Holen Sie sich die Stockscreener-App
5.40
0.18%
-0.010
Handel nachbörslich:
5.40
Schlusskurs vom Vortag:
$5.41
Offen:
$5.37
24-Stunden-Volumen:
655.72K
Relative Volume:
0.60
Marktkapitalisierung:
$916.40M
Einnahmen:
$596.48M
Nettoeinkommen (Verlust:
$123.72M
KGV:
9.8468
EPS:
0.5484
Netto-Cashflow:
$106.59M
1W Leistung:
-0.74%
1M Leistung:
+16.63%
6M Leistung:
+56.52%
1J Leistung:
+61.68%
1-Tages-Spanne:
$5.37
$5.42
1-Wochen-Bereich:
$5.33
$5.45
52-Wochen-Spanne:
$2.37
$5.72
Curevac N V Stock (CVAC) Company Profile
Vergleichen Sie CVAC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CVAC
Curevac N V
|
5.40 | 916.40M | 596.48M | 123.72M | 106.59M | 0.5484 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Curevac N V Stock (CVAC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-13 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-25 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-06-08 | Eingeleitet | SVB Securities | Outperform |
| 2023-01-19 | Hochstufung | UBS | Neutral → Buy |
| 2023-01-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-01-21 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-01-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Hold |
| 2021-06-17 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Underperform |
| 2021-04-26 | Eingeleitet | Guggenheim | Neutral |
| 2020-12-10 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2020-09-08 | Eingeleitet | BofA Securities | Buy |
| 2020-09-08 | Eingeleitet | Credit Suisse | Neutral |
| 2020-09-08 | Eingeleitet | Jefferies | Hold |
Alle ansehen
Curevac N V Aktie (CVAC) Neueste Nachrichten
Private-Public Deal Momentum Grows, Yet Megamergers Stay Elusive - Investing.com
BioNTech SE Announces Acquisition of CureVac N.V. - TipRanks
Germany: BioNTech to acquire CureVac in all-stock transaction - Investors in Healthcare
BioNTech to Acquire CureVac in Strategic Move - TipRanks
CureVac agrees to pay Biontech termination fee Of $43.8 mln under specified circumstances - MarketScreener
5 Stocks To Ride The German Market RallyCureVac (NASDAQ:CVAC), BioNTech (NASDAQ:BNTX) - Benzinga
BioNTech to Acquire CureVac in US$1.25 Billion All-Stock Transaction - Global Legal Chronicle
There's No Escaping CureVac N.V.'s (NASDAQ:CVAC) Muted Revenues Despite A 50% Share Price Rise - simplywall.st
CureVac’s SWOT analysis: mRNA pioneer’s stock faces pivotal year ahead By Investing.com - Investing.com Nigeria
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, KNW, SOAR, HLGN on Behalf of - Bluefield Daily Telegraph
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, KNW, SOAR, HLGN on Behalf of Shareholders - TradingView
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BioNTech CureVac Acquisition Boosts Cancer Drug Pipeline - Industry Leaders Magazine
CureVac (CVAC) Receives Downgrade and Price Target Reduction fro - GuruFocus
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer - GlobeNewswire
Jefferies cuts CureVac stock rating to hold on BioNTech acquisition By Investing.com - Investing.com UK
BioNTech: Oddo BHF raises target price - marketscreener.com
BioNTech to buy CureVac in USD 1.25 billion all-stock deal - Medical Dialogues
CureVac Stock: BioNTech's Billion-Dollar Takeover Bid - sharewise
BioNTech (BNTX) to Acquire CureVac in $1.25 Billion All-Stock De - GuruFocus
CureVac (CVAC) Downgraded by Jefferies Analyst After BioNTech Acquisition Agreement | CVAC Stock News - GuruFocus
BioNTech Announces Strategic Transaction to Acquire CureVac in P - GuruFocus
BioNTech Announces Strategic Acquisition of CureVac - TipRanks
Biontech’s $1.25B Curevac buyout removes mRNA lawsuit uncertainty - BioWorld MedTech
BioNTech to Acquire CureVac in $1.25B Deal - USA Herald
BioNTech's Acquisition Of CureVac Brings Complementary Method To Target Cancer (BNTX) - Seeking Alpha
5 Firms Guide $1.25B BioNTech, CureVac Oncology Deal - Law360
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, SOAR, MTWO on Behalf of Shareholders - MarketScreener
BioNTech to acquire CureVac in $1.25 billion all-stock deal By Investing.com - Investing.com South Africa
BioNTech to Acquire CureVac to Expand mRNA Cancer Therapies - N24.com.tr
BioNTech buys mRNA, courtroom rival CureVac in all-stock deal - BioPharma Dive
Watkins Advises on BioNTech’s US$1.25 Billion Acquisition of CureVac - Latham & Watkins LLP
M&A News: BioNTech (BNTX) Acquires CureVac in $1.25 Billion Deal - TipRanks
CureVac Stock Soars on BioNTech Buyout - Schaeffer's Investment Research
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal - Benzinga
BioNTech Buys CureVac For $1.25 Billion In Stock Deal - Finimize
CureVac, TELUS International, Oracle And Other Big Stocks Moving Higher On Thursday - Benzinga
COVID-19 Vaccine Maker BioNTech Buys CureVac as It Aims for Cancer Treatments - Investopedia
CureVac’s SWOT analysis: mRNA pioneer’s stock faces pivotal year ahead - Investing.com
BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals - marketscreener.com
Vaccine developer with Boston HQ acquired for $1.25B - NBC Boston
CureVac's SWOT analysis: mRNA pioneer's stock faces pivotal year ahead By Investing.com - Investing.com India
Sector Update: Health Care Stocks Lean Lower Premarket Thursday - MarketScreener
BioNTech to Buy CureVac for $1.25 Billion for Cancer Boost - Bloomberg
M&A News: BioNTech Snaps Up CureVac in $1.25B Deal to Supercharge Cancer Pipeline - TipRanks
Germany's BioNTech to buy CureVac to boost cancer research - Yahoo
BioNTech to buy former Boston Covid vaccine rival for $1.25B - The Business Journals
CVAC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CureVac N.V. Is Fair to Shareholders - Business Wire
BioNTech, CureVac Agree to All-stock Purchase Deal - MarketScreener
Oracle and CureVac rise premarket; Boeing and GameStop fall By Investing.com - Investing.com UK
BioNTech to Buy CureVac in All-Stock Deal - marketscreener.com
Finanzdaten der Curevac N V-Aktie (CVAC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):